Astellas gets EU approval for AML drug Xospata

The European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia (AML), cementing its lead over a rival dr

Seattle Genetics plans to file breast cancer drug tucatinib

Seattle Genetics has announced plans to file its breast cancer drug tucatinib after the drug met targets in a heavily pre-treated group of patients with advanced disease.

AZ’s new cancer drugs drive another stellar quarter

GSK's PARP drug Zejula approved in wider ovarian cancer popu...

The FDA has approved GlaxoSmithKline’s Zejula (niraparib) in a wider ovarian cancer indication, the first time a PARP class drug has been approved in a wider group of patients without the B

BMS gets a much-needed win with Opdivo in first-line lung ca...

Ipsen adds Blueprint's FOP rare disease drug to pipeline for...

Ipsen has added to its rare diseases pipeline after striking an agreement with US biotech Blueprint for a  licence to develop and market a drug for the rare disease fibrodysplasia ossifican